Hepatocellular Carcinoma Market 2024: Opportunity Analysis and Forecasts

"The Latest Research Report OpportunityAnalyzer: Hepatocellular Carcinoma - Opportunity Analysis and Forecasts to 2024 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

About Hepatocellular Carcinoma Market

Liver cancer is the second leading cause of cancer related death in the world in men and the sixth leading cause of cancer death in women. Hepatocellular carcinoma (HCC) is the most dominant form of liver cancer, accounting for approximately 85% of liver cancer cases. The prognosis of HCC is dependent on the stage of the disease at diagnosis. However, even with treatments such as surgical resection, liver transplantation, and ablative therapies, which are only suitable for early-stage HCC patients, the majority of patients are likely to progress onto the advanced stages of the disease.

Highlights
Key Questions Answered

Nexavar, approved in 2007, is the only available targeted treatment option for patients with advanced HCC and has dominated the HCC market in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) since its launch.
The current late and early stage pipeline is very strong and diverse. Which drug will have the biggest impact on the market? What strategies are developers undertaking to overcome the high risk of clinical trial failure?
Nexavar will lose patent protection within the forecast period. How will this impact the HCC market and will new market entries be able to stabilize the HCC market?

Get Sample copy of this Report @ https://www.marketresearchreports.biz/sample/sample/676699

Table of Contents

1 Table of Contents 9
1.1 List of Tables 14
1.2 List of Figures 18

2 Introduction 20
2.1 Catalyst 20
2.2 Related Reports 21
2.3 Upcoming Reports 21

3 Disease Overview 22
3.1 Etiology and Pathophysiology 23
3.1.1 Etiology 23
3.1.2 HBV Infection 24
3.1.3 HCV Infection 24
3.2 Surveillance of HCC 25
3.3 Alpha-Fetoprotein and other Biomarkers 27
3.4 Pathophysiology 28
3.5 Clinical Staging and Treatment Guidelines 29
3.6 Prognosis and Progression 33

4 Epidemiology 34
4.1 Disease Background 34
4.2 Risk Factors and Comorbidities 35
4.3 Global Trends 37
4.3.1 Incidence 37
4.3.2 Relative Survival 38
4.3.3 Stage at Diagnosis 40
4.4 Forecast Methodology 41
4.4.1 Sources Used 46
4.4.2 Sources Not Used 49

View Report @ https://www.marketresearchreports.biz/reports/676699/opportunityanalyzer-hepatocellular-carcinoma-opportunity-analysis-and-forecasts-to-2024-market-research-reports

4.4.3 Forecast Assumptions and Methods 50
4.5 Epidemiological Forecast of HCC (2014-2024) 53
4.5.1 Diagnosed Incident Cases of HCC 53
4.5.2 Age-Specific Diagnosed Incident Cases of HCC 55
4.5.3 Sex-Specific Diagnosed Incident Cases of HCC 56
4.5.4 Age-Standardized Diagnosed Incidence of HCC 58
4.5.5 Diagnosed Incident Cases of HCC by BCLC Stages 59
4.5.6 Diagnosed Incident Cases of HCC with HBV and HCV Comorbidities 61
4.5.7 Five-Year Diagnosed Prevalent Cases of HCC 63
4.6 Discussion 65
4.6.1 Epidemiological Forecast Insight 65
4.6.2 Limitations of the Analysis 66
4.6.3 Strengths of the Analysis 67

5 Current Treatment Options 68
5.1 Overview 68
5.2 Product Profiles - Major Brands 70
5.2.1 Nexavar (sorafenib) 70
5.3 Therapy Approaches 75
5.3.1 Early-Stage HCC Treatment 75
5.3.2 Intermediate and Advanced-Stage HCC Treatment 80
5.4 Other Treatments 85
5.4.1 Adjunctive Therapy and Treatment of Underlying Diseases 85
5.4.2 Systemic Chemotherapy 85
5.4.3 Radiation Therapy 86

6 Unmet Needs Assessment and Opportunity Analysis 87
6.1 Overview 87
6.2 Unmet Needs Analysis 87
6.2.1 Improved Treatability of Late-Stage HCC (First and Second Line) 87
6.2.2 Better Prognostic Biomarkers 89
6.2.3 Safe and Efficacious Adjuvant and Neoadjuvant Therapies 91
6.2.4 Better HCC Surveillance and Prophylactic Treatments 94

Send An Enquiry Request @ https://www.marketresearchreports.biz/sample/enquiry/676699

7 R&D Strategies 97
7.1 Overview 97
7.2 Treatments for Nexavar-Refractory Patients 97
7.3 C-Met as a Molecular Target for HCC as well as a Potential Biomarker 98
7.4 HCC as an Add-on Indication for Marketed Products 98
7.5 Multi-kinase Inhibitors Remain Well Represented in the Early- and Late-Stage Pipeline 98
7.6 Clinical Trial Design 99
7.6.1 Clinical Trial Failures 2007-2015 99
7.6.2 HCC Phase III Clinical Trial Design 2015 101
7.6.3 Clinical Trial Design Cornerstones 103

8 Pipeline Assessment 105
8.1 Overview 105
8.2 Promising Drugs in Clinical Development 106
8.2.1 Multi Kinase Inhibitors 107
8.2.2 Lenvima (lenvatinib) 108
8.2.3 Stivarga (regorafenib) 114
8.2.4 Cometriq (cabozantinib) 119
8.2.5 Tivantinib (ARQ 197) 124
8.2.6 Pexa-Vec (pexastimogene devacirepvec) 132
8.2.7 Cyramza (ramucirumab) 136
8.2.8 Pegargiminase (ADI-PEG 20) 143
8.2.9 Livatag (doxorubicin Transdrug) 147
8.2.10 ThermoDox (Heat-Activated Liposomal Encapsulation of Doxorubicin) 151
8.2.11 Peretinoin (polyprenoic acid) 156
8.3 Innovative Early-Stage Approaches 161
8.3.1 Overview 161
8.3.2 Immunotherapies 163

9 Pipeline Valuation Analysis 167
9.1 Overview 167
9.2 Clinical Benchmark of Key Pipeline Drugs 168
9.2.1 First-Line Therapy for Patients with Advanced HCC 168
9.2.2 Second-Line Therapy for Patients with Advanced HCC 169
9.2.3 Adjunctive Therapy Following Resection/Ablation or RFA 172
9.3 Commercial Benchmark of Key Pipeline Drugs 173
9.3.1 First-Line Therapy for Patients with Advanced HCC 173
9.3.2 Second-Line Therapy for Patients with Advanced HCC 174
9.3.3 Adjunctive Therapy Following Resection/Ablation or RFA 176
9.4 Competitive Assessment 178
9.4.1 First-Line and Second-Line Therapy for Patients with Advanced HCC 178
9.4.2 Adjunctive Therapy Following Resection/Ablation or RFA 180
9.5 Top-Line 10-Year Forecast 182
9.5.1 US 185
9.5.2 5EU 187
9.5.3 Japan 188

10 Appendix 189
10.1 Bibliography 189
10.2 Abbreviations 212
10.3 Methodology 216
10.4 Forecasting Methodology 216
10.4.1 HCC Incidence Patients 216
10.4.2 Progression 217
10.4.3 Percent Drug-Treated Patients 219
10.4.4 Drugs Included in Each Therapeutic Class and Patient Distributions Not Included in HCC Sales 219
10.4.5 Launch and Patent Expiry Dates 221
10.4.6 General Pricing Assumptions 222
10.4.7 Individual Drug and Pipeline Assumptions 223
10.4.8 Generic Erosion 230
10.5 Physicians and Specialists Included in this Study 231
10.5.1 Primary Research - Prescriber Survey 232
10.6 About the Authors 233
10.6.1 Author 233
10.6.2 Reviewer 233
10.6.3 Epidemiologists 234
10.6.4 Global Head of Healthcare 235
10.7 About GlobalData 236
10.8 Disclaimer 236

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz

This release was published on openPR.